Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMAGIN 4: LY2605541 vs insulin glargine in type 2 diabetes on bolus insulin lispro
jRCT2080221676Phase 3
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2011
- Modality
- Recombinant Proteins and Enzymes, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of insulin peglispro in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Eli Lilly and Company.
02
Drugs
insulin peglispro
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCT2080221676.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221676.